Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features.
Cure51 has raised $16.3M in total funding. The most recent round was Seed. The last funding was announced in March 2024.
Cure51's investors include Hitachi Ventures, Sofinnova Partners, Life Extension Ventures, Olivier Pomel, Xavier Niel.
Cure51 is headquartered in Paris, France.
Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features.
Cure51 is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cure51 — Funding & Investors." VCBacked, March 19, 2024, https://www.vcbacked.co/company/cure51. Accessed July 20, 2026.
VCBacked. (2024). Cure51 — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/cure51
{{cite web |title=Cure51 — Funding & Investors |url=https://www.vcbacked.co/company/cure51 |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated